Radically different
AI is booming. New use cases are emerging each day. To capitalize on the technology’s potential, enterprises require data at scale. In many cases, though, the relevant information is blocked or unstructured, which limits its use by AI models.
To understand this challenge, consider the foundation of the web itself. The web was not designed for the automated discovery and retrieval that new AI applications demand. Overcoming this inherent design constraint requires infrastructure.
The next frontier in AI may depend on a new web data infrastructure layer that can enable models to discover and map this ever-expanding digital realm. This layer must be able to navigate hundreds of millions of existing web domains and billions of new URLs created each week, delivering real-time information and overcoming technical barriers.
“The data suggests there’s far more data out there,” says Or Lenchner, CEO of Bright Data, a web data collection platform. “Think of the universe: It’s out there, but you don’t know what you don’t know.”
While early AI breakthroughs were driven by scaling training data and model size, organizations are now encountering a fundamental bottleneck: They need to keep pace with the dynamic, unstructured, and constantly evolving nature of web data in order to ground outputs in current and verifiable information. AI performance increasingly depends not just on model architecture but on a system’s compute, networking, retrieval, and data engineering capabilities—that is, the system’s ability to quickly and reliably retrieve data that is fresh, relevant, and trustworthy.
Traditional model training relies on snapshots of information collected at a particular point in time. Training AI on such static data is no longer sufficient. To track fluctuations such as competitor pricing, consumer sentiment, and market trends, companies need a constant feed of new information, pulling data in real time along with relevant context. Their infrastructure must therefore be able to handle millions of simultaneous interactions across websites that vary by geography, language, format, and access rules.
“If it can’t retrieve real-time information, it lacks context,” Lenchner says. “In a business setting, that’s not acceptable anymore. Stale answers lead to bad decisions and disappointed consumers.”
Speed is not merely a matter of convenience; it’s a matter of necessity. Today’s organizations operate in environments where prices, inventory, markets, security threats, and customer behavior change continuously. Delayed data retrieval can reduce the usefulness of an otherwise sophisticated model.
Using live, high-quality web data can also reduce AI hallucinations because the model has a more relevant knowledge base. This builds user trust. In fact, one survey found that 56% of AI practitioners said businesses need access to real-time web data to improve trust in AI outputs. To ensure the model runs efficiently and effectively, the information must also be pared down to the appropriate essentials.
Despite the introduction of retrieval-augmented generation (RAG), where models pull in external data at the moment of a query, many AI systems still struggle to deliver outputs that are current, contextually relevant, and trustworthy in operational settings. According to Gartner, 60% of AI projects that are not supported by AI-ready data—accurate, structured, organized, and contextualized—will be abandoned by the end of the year.
This is because large-scale retrieval alone does not solve the problem. As Lenchner puts it, “You need to retrieve data at scale, but also in real time. Latency becomes an issue because of the end user who is waiting for the output.”
Accessing fresh, AI-ready data at scale introduces technical and structural challenges. In practice, many enterprise systems combine public web retrieval with APIs, licensed datasets, and proprietary internal data in their AI applications. Integrating these fragmented sources into a timely and usable knowledge layer requires specialized capabilities. Some research has found that 97% of AI organizations depend on real-time web data infrastructure, but 90% feel boxed in by various restrictions. Companies are increasingly developing technical approaches to navigate these constraints.
Lenchner draws this metaphor: “Think of the trained model as intelligence and relevant data as knowledge. A powerful intelligence layer sitting on top of a hollow knowledge layer is like a genius who knows nothing—useless in practice. Intelligence and knowledge have to come together.”
A new layer of web data infrastructure can address this developing need for stronger AI inputs by enabling discovery of data, real-time access, and tailoring to a specific context. As Lechner describes it, “It’s all about collecting data at scale, super-low latency, without being blocked.”
Rather than relying on increased computing power, this type of platform emulates human browsing behavior to access available content and transform raw code into structured data feeds. It can work with websites that might not interact with traditional scraping tools, such as those heavy in JavaScript, or with aggressive antibot software.
As Lenchner explains, “It’s basically having infrastructure that can mimic a web user with identifying information—IP address, location, and 1,000 more parameters. And at scale. Think of doing that 80 billion times a day for millions of websites. And every single time, you are looking exactly as the website expects you to look.”
Of course, continuous retrieval introduces new data governance challenges. To address them, platforms can enforce strict compliance protocols aligned with global privacy frameworks, such as the EU’s General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA). They can also be limited to openly accessible, public information, avoiding paywalls or private logins. Any networks used can be vetted and consent-based, and incentives can be provided to owners of IP addresses. In this way, systems can be designed to comply with tightening regulation.
Such complex capabilities do not come easy. “When this is critical infrastructure for a company,” Lenchner says, “doing it in-house becomes a full-time engineering problem that competes with the actual AI work.” Addressing this complexity requires organizations to commit significant resources, leading many to seek specialized platforms designed specifically for data retrieval, orchestration, and observability.
Real-time data retrieval is changing what AI systems can do inside organizations. For example, a retail company can use public information to enable a dynamic pricing engine, and global brands can track trademark infringements.
As the ecosystem matures, organizations that invest in this emerging data infrastructure layer will be better positioned to build AI systems that are more responsive, reliable, and aligned with real-world conditions—AI systems that can continuously adapt using current web data. Over time, the distinction between AI models and the infrastructure that feeds them may even begin to disappear.
As Lenchner says, “The world is changing. And everything that is happening in the world is being uploaded to the public web. The amount of new data that is being generated is growing and accelerating.”
To learn more from Bright Data, read the Data for AI 2026 report.
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.
The common cold comes for us all—often more than once a year. And there is no way to prevent it. The best you can do is take vitamin C and stay away from people with the sniffles.
Now the payment company Stripe, founded by brothers Patrick and John Collison, says it will fund a new $500 million nonprofit whose goal is preventing both the common cold and the flu. Its eventual aim is to get rid of respiratory viruses altogether.
The new organization, called Intercept, will use grants and investments to back prevention approaches, including vaccines, as well as large-scale air-cleaning systems for schools, offices, and other public spaces.
In addition to Stripe, other funders include Anthropic, Flu Lab, and the OpenAI Foundation, as well as Bill Gates and several traders at the quantitative investing fund Jane Street Capital, according to an Intercept spokesperson.
“I think we treat respiratory infections as a minor nuisance, but have really underweighted the burden that they impose on society,” says Nan Ransohoff, the Stripe executive leading the initiative along with Charlie Petty, a venture capitalist who joined Stripe this year. On average, people spend 5% of their lifetime fighting a cold or the flu, according to Ransohoff.
Despite that, drug companies put relatively little effort into preventing colds. Part of the problem is that the sniffles are caused by more than 200 different viruses, according to the American Lung Association, with rhinoviruses being the most common culprits. There are so many that it typically doesn’t pay to try to stop any one of them with a vaccine. “When pharma companies look at it, it’s not as attractive as other things they could work on,” says Ransohoff. “So it hasn’t attracted the resources.”
Stripe previously organized a $1.8 billion program called Frontier to encourage the development of carbon removal technology, as a way of countering climate change. Ransohoff says removing carbon from the atmosphere and getting rid of respiratory viruses are similar in that each is “technically possible” but they “lack commercial incentives.”
The concept for Intercept took shape after Ransohoff started talking to David Veesler, a structural biologist and vaccine designer at the University of Washington, who argued that it’s possible to come up with broad countermeasures that work against many viruses at once.
“He effectively sort of nerd-sniped me,” Ransohoff says of Veesler. “He convinced me that this is technically possible. He also helped me understand that some of the reasons that this hasn’t been done before was sort of an incentive problem.”
Veesler says the growing tool kit available to scientists includes RNA drugs, antibodies, and computational protein design. For instance, one idea is to engineer virus-grabbing proteins that people could spray in their nasal passages, to catch viruses before they cause infection.
“Most people just accept these viruses as a fact of life, and that got us thinking: Do we have to accept it?” says Veesler. “The more we thought about it, the more we realized that many of these problems have not been worked on with modern technologies.”
The project takes inspiration from efforts to fight the covid-19 virus, where Veesler’s group was among those involved in the speedy development of vaccines, antiviral drugs, and antibodies.
According to Ransohoff, Intercept’s advisors will include Peter Marks, a former top FDA official, as well as Moncef Slaoui, the pharmaceutical executive who led the US coronavirus vaccine effort, Operation Warp Speed.
A key challenge for Intercept will be coming up with ways to counter many viruses at one time. That accounts for the interest in air-cleaning technology, such as using strong ultraviolet light to inactivate viruses. The idea, the group says, is to remove them from the air in the same way municipalities remove impurities from the water supply before it’s piped to people’s homes.
The US funds about $6.5 billion a year in virus research through the National Institute of Allergy and Infectious Disease, or NIAID. But that agency’s budget hasn’t grown in recent years, leaving more room for private philanthropy.
And Stripe’s Collison brothers have become some of the most reliable philanthropists in viral research. After giving away “fast grants” to help labs during the covid-19 pandemic, they later joined other donors who committed $650 million to establish the Arc Institute in Palo Alto, California, which has developed AI models for biological research.
“The diversity of viruses is just too large and seems daunting, so people don’t even try,” says Veesler. “I’m happy that someone is ready to help scientists, not accepting the status quo, and doing something different.”
Nature Medicine, Published online: 24 June 2026; doi:10.1038/s41591-026-04508-1
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
Nature Medicine, Published online: 24 June 2026; doi:10.1038/s41591-026-04532-1
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
Nature Neuroscience, Published online: 24 June 2026; doi:10.1038/s41593-026-02368-z
Brain aneurysms are a major cause of stroke worldwide, yet the cellular mechanisms that drive vessel instability remain poorly defined. A combined single-cell and spatial transcriptomic atlas of aneurysm tissue shows previously unrecognized interplay between scarring-associated fibroblasts and osteoclast-like macrophages that is associated with aneurysm formation and rupture.
Young people are among the most intensive users of digital and generative artificial intelligence (GenAI)–enabled mental health tools, yet they remain underrepresented in the research and design processes that shape these technologies. Although participatory approaches such as co-design and patient and public involvement are widely endorsed as best practices, youth involvement in digital youth mental health (DYMH) research is often inconsistent, superficial, or limited to late-stage consultation. This participation gap risks producing interventions that are misaligned with young people’s lived experiences, priorities, and vulnerabilities, particularly in the context of rapidly evolving and scalable GenAI systems. This Viewpoint aims to reexamine the underlying drivers of the participation gap in DYMH research; clarify how participation is conceptualized and implemented across disciplines; and propose concrete, actionable recommendations to support more meaningful and consistent youth involvement across the research life cycle. We draw on interdisciplinary literature from digital mental health, human-computer interaction, child-computer interaction, and health research policy. Our Viewpoint integrates conceptual frameworks (eg, Lundy’s model of participation), existing reviews of co-design practices, and emerging evidence on GenAI in mental health. We adopt a life cycle–oriented perspective to examine how youth participation is distributed across stages of research and development, including problem formulation, design, implementation, and evaluation. We identify 3 interrelated drivers of the participation gap. First, conceptual and linguistic fragmentation obscures what participation entails in practice, with terms such as co-design, participatory design, user-centered design, and patient and public involvement used inconsistently across disciplines. Second, youth involvement is uneven across the research life cycle, with participation often concentrated in early ideation or usability testing but largely absent from upstream decision-making and downstream evaluation. Third, institutional barriers—including ethics review processes, consent requirements, funding constraints, and adult-centric research norms—systematically limit meaningful youth partnership. These challenges are amplified in the context of GenAI, where opaque “black box” systems, simulated therapeutic interactions, and rapid deployment cycles introduce distinct risks if youth perspectives are not integrated. We propose a set of minimum expectations to address these gaps, including explicit specification of participatory models, life cycle mapping of youth involvement, reporting of youth influence on decisions, dedicated funding for participation, proportional ethics frameworks, and mechanisms for youth-informed governance of GenAI systems. Closing the participation gap in DYMH research is both an ethical imperative and a practical necessity. Moving beyond aspirational commitments requires embedding youth participation as a standard, resourced, and accountable component of research, design, and governance. In the context of rapidly evolving digital and GenAI technologies, failure to do so risks producing interventions that are scalable but not safe, credible, or responsive to the needs of young people.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/67c65c203969ea3255b58718960137bf" />
Background: Generative artificial intelligence (GenAI) chatbots have the potential to provide personalized mental health support to individuals at scale. Objective: This study evaluates the feasibility and usage patterns of the Safespace GenAI chatbot, an artificial intelligence (AI)–driven smartphone app that offers a large language model–powered interactive chatbot to support mental health. Methods: Using a mixed methods approach, we explored baseline attitudes toward GenAI chatbots and chatbot usage patterns, conducted a qualitative content analysis of participants’ experiences, and descriptively assessed patterns related to preintervention depressive symptoms. The study included an initial sample of 42 university students, 20 of whom actively used the chatbot over 2 to 4 weeks, generating 286 user-chatbot interactions. Results: Preintervention surveys indicated that the majority of participants anticipated that the chatbot would be helpful (27/42, 64%) and that they trusted its privacy safeguards (39/42, 93%). Usage patterns suggested that the highest levels of interaction occurred early in the morning and late at night, when peer and professional support may be inaccessible. The qualitative analysis indicated that participants appreciated using the chatbot for reflection as a blended-care tool between their counseling sessions, while also naming technical barriers and specific design needs required to sustain engagement. In addition, our exploratory analyses descriptively showed that participants with elevated depression scores engaged in emotional disclosure during 99% (38 sessions with 8 participants) of their sessions, compared to 84% (26 sessions of 12 participants) of those with low symptoms. Due to the small sample size, future adequately powered studies are needed to inferentially examine these observed patterns. Conclusions: These findings provide initial insights into the usage and engagement dynamics of the Safespace GenAI chatbot and highlight directions for future research to optimize GenAI-driven mental health interventions. Trial Registration: AEA Registry AEARCTR-0013291; https://doi.org/10.1257/rct.13291-1.0
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/8ea8d6d9a0e05f3fdb856f007cfd4549" />
The pharmaceutical giants behind the monumentally successful weight loss drugs Wegovy and Mounjaro have been teasing an expansion into other aesthetic fields like hair loss or skin care.
Now, one of them is making a move, investing in a small startup developing a medication to spur hair growth, and potentially also treat endometriosis.
On Wednesday, Absci announced that it raised $100 million from a group led by Eli Lilly. Lilly brought the lion’s share of the funding, handing over $40 million in exchange for equity in Absci, which is publicly traded on the Nasdaq.